Treace Medical Q3 Revenue $48.3M; Net Loss Improves 23%

Treace Medical Concepts reported its third quarter 2026 financial results, with revenue at $48.3 million, a 4% decrease year-over-year. The company improved its net loss by 23% to $(12.6) million and its Adjusted EBITDA by $2.9 million to $0.3 million compared to the prior year period. Year-to-date cash usage was reduced by 53%. Treace updated its full-year 2026 revenue guidance to $206-$210 million and improved its Adjusted EBITDA guidance to a loss of $1.0-$2.0 million.